Sudarshan Pharma Industries Ltd
Sudarshan Pharma Industries Ltd Q4 FY26 Results & Presentation Highlights: Revenue ₹220.92 Cr, EBITDA margin 9.14%
Q4 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Sudarshan Pharma Industries Ltd's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Revenue from Operations for Q4 March 2026: ₹220.92 Cr (Page 41) - Revenue from Operations for Q4 March 2025: ₹168.01 Cr (quarter ended Dec 2025, closest quarterly prior data) - Year-on-year growth inf Quarterly EBITDA (Q4 March 2026): INR 20.19 Cr with an EBITDA margin of 9.14%.
From Sudarshan Pharma Industries Ltd's Q4 FY26 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Revenue from Operations for Q4 March 2026: ₹220.92 Cr (Page 41)
- Revenue from Operations for Q4 March 2025: ₹168.01 Cr (quarter ended Dec 2025, closest quarterly prior data)
- Year-on-year growth inferred for Q4 Mar 2026 vs Mar 2025 is approximately 31.4% (₹220.92 Cr vs ₹168.01 Cr)
- FY 2026 Revenue from Operations: ₹703.06 Cr vs FY 2025 ₹505.05 Cr, a 39.2% increase (Page 42)
- Outlook for FY 26-27 export turnover target: Minimum ₹100 Cr (Page 13)
2 more points management made on revenue & sales performance
Profitability & Margins
See what Sudarshan Pharma Industries Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Nutraceuticals Plant project: Rs. 2.5 Cr. project cost with Rs. 1.15 Cr. machinery cost (2019-2020).
- Oral liquid and capsule manufacturing unit erected at Palghar (2021-2022).
- Vitamin B1 and B6 manufacturing under Production Linked Incentive (PLI) schemes; new products developed and to be first made in India (2021-2022).
- New unit development in Palghar (2023-2024).
- Acquisitions: Ratna Lifesciences & 51% of Ishwari Healthcare (2024-2025).
- Proposed allotment of FCCB worth 20 Million USD (2025-2026).
- Capex of Rs. 25.50 Cr. acquired from Srigen Lifesciences Private Limited (2025-2026).
2 more points management made on capital expenditure plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sudarshan Pharma Industries Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Sudarshan Pharma Industries Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹221 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sudarshan Pharma Industries Ltd's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Chemfab Alkalis Ltd (Q4 FY26)
Chlor Alkali segment: ₹55.63 crore (down 1.21% YoY from ₹56.31 crore) . Key investor presentation takeaways from Chemfab Alkalis Ltd's Q4 FY26 investor presenta
- Innovassynth Technologies (India) Ltd (Q4 FY26)
Order book improved by approximately INR 60 crore during the quarter, indicating strong customer demand and revenue visibility. Key investor presentation takeaw
- Jubilant Agri & Consumer Products Ltd (Q4 FY26)
Q4 FY26 Revenue from Operations: INR 4,852 MN, up 22% YoY from INR 3,983 MN in Q4 FY25 (Page 19) . Key investor presentation takeaways from Jubilant Agri & Cons
- Bhansali Engineering Polymers Ltd (Q4 FY26)
Q4 FY26 Revenue from Operations: ₹341.6 crores, a -1.0% year-on-year (YoY) decline (Page 8, 28). Key investor presentation takeaways from Bhansali Engineering P
Frequently Asked Questions
What were Sudarshan Pharma Industries Ltd Q4 FY26 results?
Revenue from Operations for Q4 March 2026: ₹220.92 Cr (Page 41) - Revenue from Operations for Q4 March 2025: ₹168.01 Cr (quarter ended Dec 2025, closest quarterly prior data) - Year-on-year growth inf Quarterly EBITDA (Q4 March 2026): INR 20.19 Cr with an EBITDA margin of 9.14%.
What is Sudarshan Pharma Industries Ltd share price analysis?
Sudarshan Pharma Industries Ltd currently shows a neutral. The stock trades at a P/E of 39.4 with a market cap of ₹990 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sudarshan Pharma Industries Ltd planning capital expenditure?
Nutraceuticals Plant project: Rs.
Keep Sudarshan Pharma Industries Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.